Apogee Therapeutics, Inc. (APGE)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

135.07 on 4 Sep 2026

0 buys1 sale at will35 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$255.84M

Free cash flow

$232.60M

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
5 Aug 2026	Dambkowski Carl Chief Medical Officer	Sold on a plan	$737.94K	3.2%
8 Jul 2026	HENDERSON MICHAEL THOMAS Chief Executive Officer	Sold on a plan	$2.67M	2.0%
1 Jul 2026	Dambkowski Carl Chief Medical Officer	Sold on a plan	$730.07K	3.0%
22 Jun 2026	HENDERSON MICHAEL THOMAS Chief Executive Officer	Sold on a plan	$10.60M	7.3%
22 Jun 2026	Dambkowski Carl Chief Medical Officer	Sold on a plan	$3.50M	12.8%
10 Jun 2026	HENDERSON MICHAEL THOMAS Chief Executive Officer	Sold on a plan	$1.67M	1.8%

7out of 100

Profitability 0

Financial strength 20

Growth n/a

Insiders 0

Strongest on financial strength (20), weakest on insiders (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$173.96M

36 sales

Planned sales

97%

under a 10b5-1 plan